3 ms·
It's disappointing that more biotech isn't ultimately funded by YC. I'm sure it's just due to the cost of starting and running a pre-revenue biotech is much hig
by mylons 12y ago
It's disappointing that more biotech isn't ultimately funded by YC. I'm sure it's just due to the cost of starting and running a pre-revenue biotech is much higher than a company starting a pure software product.
That said, YC funding science is fantastic. Even if it is just 1 company, thus far. Biotech should be a nice hedge in the portfolio.
- namenotrequired 12y agoAccording to the article, it's one of five biotech startups in this batch.
- mylons 12y agobut it's the only one publicly listed in their portfolio at this date.